Dr. Luis Garegnani from Argentia wrote an opinion piece on Ivermectin not having enough evidence behind it in BMJ Journals. Dr. Pierre Kory of the FLCCC disagrees. Both doctors debate this issue with Dr. Erin Stair as the moderator. About Luis Garegnani: Luis Garegnani is a Professor of Research methods and evidence-based medicine at Instituto…
Day: August 14, 2021
Open Forum Infectious Disease reports “Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection”
Ivermectin is an antiparasitic drug being investigated for repurposing against SARS-CoV-2. Ivermectin showed in-vitro activity against SARS-COV-2 at high concentrations. This meta-analysis investigated ivermectin in 24 randomized clinical trials (3328 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv and trial registries. Ivermectin was associated with reduced inflammatory markers (C-Reactive Protein, d-dimer and ferritin) and…
Research Square reports “Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic”
Up-to-date, there is no recognized effective treatment or vaccine for the treatment of COVID-19 that emphasize urgency around distinctive effective therapies. This study aims to evaluate the anti-parasitic medication efficacy “Ivermectin” plus standard care ((Azithromycin, vitamin C, Zinc, Lactoferrin & Acetylcystein & prophylactic or therapeutic anticoagulation if D-dimer > 1000)) in the treatment of mild/moderate and severely…